Clinical trials
Phase 1/2 Huntington Disease trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2006 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 6 |
| Active, not recruiting | 4 |
| Terminated | 4 |
| Recruiting | 3 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Wave Life Sciences USA, Inc. | 5 |
| UniQure Biopharma B.V. | 2 |
| AskBio France, SAS, a subsidiary of AskBio Inc. | 1 |
| Chaitanya Hospital, Pune | 1 |
| ExoRNA Bioscience | 1 |
| FDA Office of Orphan Products Development | 1 |
| Hoffmann-La Roche | 1 |
| Ionis Pharmaceuticals, Inc. | 1 |
| Leslie Thompson | 1 |
| Medivation, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Huntington Disease | 18 |
| Movement Disorders | 2 |
| Brain Diseases | 1 |
| Central Nervous System Diseases | 1 |
| Chorea | 1 |
| Cognition Disorders | 1 |
| Genetic Diseases, Inborn | 1 |
| Machado-Joseph Disease | 1 |
| Nervous System Diseases | 1 |
| Neurocognitive Disorders | 1 |
Trials
Showing 26 to 18 of 18. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.